Peijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study

Bulletin Express

04/09

Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.

The company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.

The announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1108148998"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108148998\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108148998?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 18:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108148998","market":"hk","top_or_hot":-1,"title":"Peijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study","media":"Bulletin Express","content":"<p>Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.</p>\n<p>The company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.</p>\n<p>The announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeijia Medical completes first U.S. patient implant in GeminiOne TEER early feasibility study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 18:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.</p>\n<p>The company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.</p>\n<p>The announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"","article_id":"1108148998","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108148998","pubTimestamp":1775731623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne®...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"沛嘉医疗在GeminiOne TEER早期可行性研究中完成首例美国患者植入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"Peijia Medical Limited (Peijia Medical) has announced the successful completion of the first patient implant in the U.S. Food and Drug Administration Early Feasibility Study for its GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system. The procedure, performed by Professor Saibal Kar at Los Robles Regional Medical Center, marks the company’s initial clinical milestone in the United States for this structural-heart intervention technology.\nThe company highlighted that, while the milestone advances GeminiOne’s clinical development, there is no assurance the device will ultimately achieve full regulatory approval or commercialization. Investors are urged to exercise caution when dealing in Peijia Medical’s shares.\nThe announcement was released on 9 April 2026 and approved by the Board, chaired by Executive Director Dr. Yi Zhang.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}